Gene · 2823
Papers1,924
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 1,924
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Concerted neuron-astrocyte gene expression declines in aging and schizophrenia. | bioRxiv | 2024 | 38260461 | PubTator, text mining | PubMed |
| Next-Generation Proteomics of Brain Extracellular Vesicles in Schizophrenia Provide New Clues on the Altered Molecular Connectome. | Biomedicines | 2024 | 38255234 | PubTator, text mining | PubMed |
| The inhibition of YTHDF3/m6A/LRP6 reprograms fatty acid metabolism and suppresses lymph node metastasis in cervical cancer. | Int J Biol Sci | 2024 | 38250152 | PubTator, text mining | PubMed |
| YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD-L1/VEGFA Axis. | Adv Sci (Weinh) | 2024 | 38247171 | PubTator, text mining | PubMed |
| FTO protein regulates the TGF-β signalling pathway through RNA N6-methyladenosine modification to induce unexplained recurrent spontaneous abortion. | FEBS J | 2024 | 38245815 | PubTator, text mining | PubMed |
| m6A demethylase ALKBH5 maintains stemness of intrahepatic cholangiocarcinoma by sustaining BUB1B expression and cell proliferation. | Transl Oncol | 2024 | 38242006 | PubTator, text mining | PubMed |
| NAT10 mediated ac4C acetylation driven m6A modification via involvement of YTHDC1-LDHA/PFKM regulates glycolysis and promotes osteosarcoma. | Cell Commun Signal | 2024 | 38233839 | PubTator, text mining | PubMed |
n6-methyladenosine-modified circular RNA family with sequence similarity 126, member A affects cholesterol synthesis and malignant progression of prostate cancer cells by targeting microRNA-505-3p to mediate calnexin. | J Cancer | 2024 | 38230215 | PubTator, text mining | PubMed |
| ALKBH5 is a prognostic factor and promotes the angiogenesis of glioblastoma. | Sci Rep | 2024 | 38221546 | PubTator, text mining | PubMed |
| CVD phenotyping in oncologic disorders: cardio-miRNAs as a potential target to improve individual outcomes in revers cardio-oncology. | J Transl Med | 2024 | 38216965 | PubTator, text mining | PubMed |
| ALKBH5 regulates paclitaxel resistance in NSCLC via inhibiting CEMIP-mediated EMT. | Toxicol Appl Pharmacol | 2024 | 38199493 | PubTator, text mining | PubMed |
| The m6A reader YTHDC2 regulates UVB-induced DNA damage repair and histone modification. | Photochem Photobiol | 2024 | 38190286 | PubTator, text mining | PubMed |
| Knockdown of fat mass and obesity alleviates the ferroptosis in Parkinson's disease through m6A-NRF2-dependent manner. | Cell Biol Int | 2024 | 38180302 | PubTator, text mining | PubMed |
| m6A-modified circARHGAP12 promotes the aerobic glycolysis of doxorubicin-resistance osteosarcoma by targeting c-Myc. | J Orthop Surg Res | 2024 | 38178201 | PubTator, text mining | PubMed |
| Identification of clinical prognostic factors and analysis of ferroptosis-related gene signatures in the bladder cancer immune microenvironment. | BMC Urol | 2024 | 38172792 | PubTator, text mining | PubMed |
| Circular RNA-circPan3 attenuates cardiac hypertrophy via miR-320-3p/HSP20 axis. | Cell Mol Biol Lett | 2024 | 38172650 | PubTator, text mining | PubMed |
| Lymphatic vessel: origin, heterogeneity, biological functions, and therapeutic targets. | Signal Transduct Target Ther | 2024 | 38172098 | PubTator, text mining | PubMed |
| M6A plays a potential role in carotid atherosclerosis by modulating immune cell modification and regulating aging-related genes. | Sci Rep | 2024 | 38168909 | PubTator, text mining | PubMed |
| Dock5 Deficiency Promotes Proteinuric Kidney Diseases via Modulating Podocyte Lipid Metabolism. | Adv Sci (Weinh) | 2024 | 38161229 | PubTator, text mining | PubMed |
| The Molecular Basis of Human ALKBH3 Mediated RNA N1 -methyladenosine (m1 A) Demethylation. | Angew Chem Int Ed Engl | 2024 | 38158383 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2823/papers?page=16